No Data
No Data
Maxim Group Upgrades Nexalin Technology(NXL.US) to Buy Rating, Announces Target Price $5
Maxim Group Upgrades Nexalin Technology to Buy, Announces $5 Price Target
Nexalin Technology Analyst Ratings
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
10-K: FY2024 Annual Report
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV